Biodesix (BDSX) Stock Price

Biodesix Price

NASDAQ·CLOSED
26.42
​
Market closed

Over the last 7 years Biodesix grew revenue by 23.3% annually, reaching 88.50 M USD. For Biodesix, the net margin of -39.8% is up versus -79.2% a few years ago. The consensus 12-month price target for Biodesix is 35.70 USD, about 35.1% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.

Biodesix stock price

Access this data via the Eulerpool API

Biodesix business model & stock analysis

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 245 full-time employees. The company went IPO on 2020-10-28. Biodesix is focused on using technologies with its artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs in lung disease. Biodesix is providing diagnostic testing services associated with blood-based lung tests; coronavirus disease tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development, and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Its blood-based lung cancer tests include Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. Biodesix also offers SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralizing Antibody testing.

Frequently asked questions about Biodesix

Analysts currently set an average price target of 33.15 USD for the Biodesix stock (median: 35.70 USD), implying +25.5 % versus the latest price. The consensus is based on 11 analyst ratings.

13 analysts currently rate the Biodesix stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Biodesix to generate revenue of 111.95 M USD and earnings per share of -2.64 USD.

Converted at the current exchange rate, the Biodesix share trades at 23.59 EUR (26.42 USD).

The Biodesix share (BDSX) is listed on 1 stock exchanges, including: NASDAQ (BDSX).

The expected revenue of Biodesix is 111.95 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biodesix is -21.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biodesix is currently -10.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biodesix stock.

The price-to-sales ratio (P/S) of Biodesix is currently 1.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biodesix stock.

The Eulerpool Quality Score for Biodesix is 3/10.

The ISIN of Biodesix is US09075X2071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biodesix is A2QFCN. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biodesix is BDSX. The ticker symbol is used to trade Biodesix shares on the stock exchange.

Fair ValueTerminal
27.48 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue per Employee
361,220.41 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website biodesix.com
Currency
USD
Initial public offering
Oct 28, 2020
ISIN
US09075X2071
Cusip
09075X108
Market capitalization
210.30 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-10.01
P/Ee 2027
-16.04
P/Ee 2028
-26.42
P/Ee 2029
-81.12
P/Ee 2030
110.08
P/S
P/Se
1.90
EV/EBIT
—
P/B Ratio
10.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-50.10 %
Last updated Oct 8, 2026, 8:33 PM

Biodesix Peer Group

Biodesix Ticker

NASDAQ · BDSX

All fundamentals and in-depth analysis of Biodesix

Our stock analysis for Biodesix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biodesix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.